Morepen Laboratories

₹94.43As of Sun 8 Nov 2026, 12:00 UTC

NSE:MOREPENLABHealthcare

Country India

PE (Fwd) 53.16

TSR 10Y CAGR 14.81%

Div yield 0.21%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.95

PE TTM 54.54

TSR TTM 98.80%

Mkt cap ₹54.27B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹106

11.78%

(84.83%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

18.06

Revenue₹B

—

15.56

14.22

16.90

18.12

18.06

18.56

3.79%

(0.32)

Revenue growth%

—

(8.60)

18.88

7.17

(0.32)

2.81

3.42

—

36.40

Gross margin%

—

31.80

31.44

35.77

34.57

36.40

36.39

34.57

4.94

Operating margin%

—

7.58

3.94

7.40

8.01

4.94

4.83

7.40

5.25

Net margin%

—

6.54

2.72

5.69

6.51

5.25

5.14

5.69

54.54

P/E ratio (avg)x

—

30.51

44.44

22.47

32.79

29.56

54.28

30.51

58.01

EV/EBITx

—

26.29

30.65

17.27

26.67

31.44

57.76

26.67

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

1.73

EPS₹

—

1.96

0.77

1.88

2.20

1.73

1.74

(3.00%)

—

(21.47)

EPS growth%

—

(60.63)

144.28

17.21

(21.47)

0.48

(2.13)

—

Bookvalue per sh₹

—

FCF per share₹

—

0.20

Dividend per sh₹

—

0.20

0.22

—

0.21

Div yield (avg)%

—

0.28

0.39

0.23

0.33

—

11.55

Payout ratio%

—

9.07

11.55

12.67

—

548.0

Shares (diluted)M

—

519.8

502.2

511.2

535.3

548.0

◌548.0

1.33%

(2.37)

Buyback yield%

—

3.39

(1.78)

(4.71)

(2.37)

◌—

(2.08)

—

D/E ratiox

—

51.74

Enterprise value₹B

—

31.02

17.19

21.61

38.69

28.04

51.74

(2.49%)

—

LT debt₹M

—

Peers (US$536.8M)

Cap (US$)

IOL Chemicals and…

575.6M

26.66x

Orchid Pharma Limited

552.2M

149.0x

Gujarat Themis Biosyn…

532.4M

86.19x

Sinotherapeutics Inc.

537.1M

181.3x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

5.549

28.31

Own earn%

—

Sh yield%

(2.16)

(1.88)

Owners

Insiders/Inst%

8.41

1.53

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

2/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

4–8

$1 testx

—

Incr. ROIC%

—

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹18.06B

3.79%

1.00×

Cost of revenue

₹11.48B

2.00%

0.93×

Operating expenses

₹5.681B

10.81%

1.30×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m